AB023 reduces dialyzer clotting compared to placebo during heparin-free dialysis, and continues to be safe and well tolerated

Presentation to include clinical data from Aronora's phase 2 study of AB023, a factor XI-targeted antibody that is being developed for the treatment and prevention of thrombosis and inflammation.